Could a common anesthetic ease severe asthma in kids?

NCT ID NCT07728851

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether inhaled ketamine can improve breathing in children aged 1 to 13 with severe asthma attacks that do not respond to standard treatments. Participants receive either nebulized ketamine or a placebo every six hours for 24 hours, alongside usual care. The study measures changes in a respiratory distress score and whether children need additional breathing support or longer hospital stays.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nebulized ketamine
What this could lead to
If effective, nebulized ketamine could offer a new rescue option for children with severe asthma attacks who do not respond to standard therapy, potentially reducing the need for breathing support.
What could go wrong
This is a small early-phase pilot trial, so results may not be conclusive. Ketamine can cause side effects like hallucinations, high blood pressure, or heart rhythm problems, especially in children.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sultan Qaboos University Hospital

    Muscat, Oman

More trials for these conditions

Other studies related to the condition(s) this trial covers.